103 related articles for article (PubMed ID: 16966961)
1. Use of beryllium lymphocyte proliferation testing for screening of asymptomatic individuals: an evidence-based assessment.
Borak J; Woolf SH; Fields CA
J Occup Environ Med; 2006 Sep; 48(9):937-47. PubMed ID: 16966961
[TBL] [Abstract][Full Text] [Related]
2. Use of the Beryllium Lymphocyte Proliferation Test (BeLPT) for screening.
Lebeau J
J Occup Environ Med; 2007 Apr; 49(4):357-8; author reply 358-9. PubMed ID: 17426515
[No Abstract] [Full Text] [Related]
3. Clinical and laboratory factors contributing to uninterpretable beryllium lymphocyte proliferation tests (BeLPT).
Smith DE; Golden AP; Stange AW; Barker E; Mroz M; Barón AE; Ghosh D; Maier L; Cragle D; Newman LS
Am J Ind Med; 2018 Jul; 61(7):592-604. PubMed ID: 29574954
[TBL] [Abstract][Full Text] [Related]
4. Significance of the blood beryllium lymphocyte proliferation test.
Newman LS
Environ Health Perspect; 1996 Oct; 104 Suppl 5(Suppl 5):953-6. PubMed ID: 8933041
[TBL] [Abstract][Full Text] [Related]
5. Screening for beryllium disease among construction trade workers at Department of Energy nuclear sites.
Welch L; Ringen K; Bingham E; Dement J; Takaro T; McGowan W; Chen A; Quinn P
Am J Ind Med; 2004 Sep; 46(3):207-18. PubMed ID: 15307119
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of serial medical surveillance for chronic beryllium disease in a beryllium machining plant.
Newman LS; Mroz MM; Maier LA; Daniloff EM; Balkissoon R
J Occup Environ Med; 2001 Mar; 43(3):231-7. PubMed ID: 11285871
[TBL] [Abstract][Full Text] [Related]
7. Beryllium health effects in the era of the beryllium lymphocyte proliferation test.
Maier LA
Appl Occup Environ Hyg; 2001 May; 16(5):514-20. PubMed ID: 11370931
[TBL] [Abstract][Full Text] [Related]
8. Rocky Flats Beryllium Health Surveillance.
Stange AW; Furman FJ; Hilmas DE
Environ Health Perspect; 1996 Oct; 104 Suppl 5(Suppl 5):981-6. PubMed ID: 8933045
[TBL] [Abstract][Full Text] [Related]
9. Chronic beryllium disease among dental technicians in Israel.
Fireman E; Kramer MR; Priel I; Lerman Y
Sarcoidosis Vasc Diffuse Lung Dis; 2006 Oct; 23(3):215-21. PubMed ID: 18038921
[TBL] [Abstract][Full Text] [Related]
10. The BeLPT: algorithms and implications.
Middleton DC; Lewin MD; Kowalski PJ; Cox SS; Kleinbaum D
Am J Ind Med; 2006 Jan; 49(1):36-44. PubMed ID: 16362939
[TBL] [Abstract][Full Text] [Related]
11. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant.
Henneberger PK; Cumro D; Deubner DD; Kent MS; McCawley M; Kreiss K
Int Arch Occup Environ Health; 2001 Apr; 74(3):167-76. PubMed ID: 11355290
[TBL] [Abstract][Full Text] [Related]
12. Beryllium Biobank 3: considerations for improving chronic beryllium disease screening.
Harber P; Su J
J Occup Environ Med; 2014 Aug; 56(8):861-6. PubMed ID: 25099414
[TBL] [Abstract][Full Text] [Related]
13. Advances in identifying beryllium sensitization and disease.
Middleton D; Kowalski P
Int J Environ Res Public Health; 2010 Jan; 7(1):115-24. PubMed ID: 20195436
[TBL] [Abstract][Full Text] [Related]
14. Optimizing BeLPT criteria for beryllium sensitization.
Middleton DC; Fink J; Kowalski PJ; Lewin MD; Sinks T
Am J Ind Med; 2008 Mar; 51(3):166-72. PubMed ID: 18181198
[TBL] [Abstract][Full Text] [Related]
15. Identification of an abnormal beryllium lymphocyte proliferation test.
Frome EL; Newman LS; Cragle DL; Colyer SP; Wambach PF
Toxicology; 2003 Feb; 183(1-3):39-56. PubMed ID: 12504341
[TBL] [Abstract][Full Text] [Related]
16. A model for optimization of biomarker testing frequency to minimize disease and cost: example of beryllium sensitization testing.
Judd NL; Griffith WC; Takaro T; Faustman EM
Risk Anal; 2003 Dec; 23(6):1211-20. PubMed ID: 14641896
[TBL] [Abstract][Full Text] [Related]
17. The beryllium lymphocyte proliferation test: Relevant issues in beryllium health surveillance.
Stange AW; Furman FJ; Hilmas DE
Am J Ind Med; 2004 Nov; 46(5):453-62. PubMed ID: 15490468
[TBL] [Abstract][Full Text] [Related]
18. Search for chronic beryllium disease among sarcoidosis patients in Ontario, Canada.
Ribeiro M; Fritscher LG; Al-Musaed AM; Balter MS; Hoffstein V; Mazer BD; Maier LA; Liss GM; Tarlo SM
Lung; 2011 Jun; 189(3):233-41. PubMed ID: 21400234
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis between CFSE flow cytometric and tritiated thymidine incorporation tests for beryllium sensitivity.
Milovanova TN
Cytometry B Clin Cytom; 2007 Jul; 72(4):265-75. PubMed ID: 17328032
[TBL] [Abstract][Full Text] [Related]
20. Interpreting borderline BeLPT results.
Middleton DC; Mayer AS; Lewin MD; Mroz MM; Maier LA
Am J Ind Med; 2011 Mar; 54(3):205-9. PubMed ID: 20957676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
